Decreased levels of FGF19 are commonly observed in obesity-related conditions such as type 2 diabetes (T2D), gestational diabetes, non-alcoholic fatty liver disease (NAFLD), and NASH, as well as in bile malabsorption conditions like cystic fibrosis (52). This evidence concerns the gene FGF19 and metabolic dysfunction-associated steatotic liver disease.